Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelodysplastic syndrome (MDS)
Biotech
Merck mulls PV program’s future while Takeda takes victory lap
Merck revealed the first look at data from a phase 2 trial of bomedemstat, while Takeda shared updated results from rusfertide's phase 3 study.
Darren Incorvaia
Dec 8, 2025 4:30pm
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Syros flunks phase 3 blood cancer trial, triggering loan default
Nov 13, 2024 10:00am
Molecular Partners tweaks AML trial over 'suboptimal exposure'
Aug 27, 2024 10:00am
New EHA data show how Gilead's $4.9B bet on CD47 imploded
Jun 14, 2024 2:03pm
